At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Olanzapine +2 moredrug
Likely dose
Olanzapine 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Olanzapine, Netupitant, and 1 other intervention for Nausea Post Chemotherapy. Completed, enrolled 50 participants across 1 site.
Detailed Summary
This is a longitudinal, one arm, prospective phase II study, designed to evaluate the efficacy of Olanzapine Netupitant and Palonosetron in the controll of nausea and vomiting induced by highly emetogenic chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNausea Post Chemotherapy
CountriesBrazil
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartDec 2020
Primary CompletionDec 2021
Study CompletionJan 2022
TodayJul 2026
First PostedDec 16, 2020
Enrollment StartDec 17, 2020
Primary CompletionDec 17, 2021
Study CompletionJan 17, 2022
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 5.5 years ago
Interventions
Olanzapinedrug
\- Olanzapine 5mg, administered once daily, during 5 days (day before chemotherapy, the D day of the chemotherapy and 3 day after chemotherapy)
Netupitantdrug
\- Netupitanto 300 mg, once daily, on chemotherapy day;
Palonesetrondrug
\- Palonosetron 0.56 mg, once daily, on chemotherapy day;